Empyrean Neuroscience
Empyrean: Revolutionizing healthcare with genetic engineering for severe neurological disorders.
Founded
2019Empyrean: Revolutionizing healthcare with genetic engineering for severe neurological disorders.
Empyrean Neuroscience, founded with the mission to revolutionize healthcare, focuses on using genetic engineering to treat severe neuropsychiatric and neurologic illnesses. The company's vision is to transform the landscape of neurological disorder treatment through innovative genetic solutions. Empyrean's primary offerings include advanced genetic therapies designed to address complex neurological conditions, aiming to provide groundbreaking treatments that significantly improve patient outcomes.
Notable figures associated with Empyrean Neuroscience include leading experts in genetic engineering and neuroscience, though specific names are not provided. The company has attracted significant interest from investors in the biotech and healthcare sectors, reflecting confidence in its cutting-edge approach. Key achievements include pioneering advancements in genetic therapy applications for neurological disorders, positioning Empyrean as a potential leader in this transformative field. The overall impact of Empyrean's work promises to set new standards in the treatment of severe neurological conditions, offering hope to patients worldwide.
Companies similar to Empyrean Neuroscience include Neurogene, Reservoir Neuroscience, Neuraly and Engrail Therapeutics.
Empyrean Neuroscience was founded in 2019.
Empyrean Neuroscience's headquarters is located in New York City, NY, US.
Empyrean Neuroscience's most recent funding round was for $22M (USD) in October 2022.
As of Oct 18, 2022, Empyrean Neuroscience has raised a total of $22M (USD).
Empyrean Neuroscience has 11 employees as of Feb 4, 2024.
Neuraly
neuralymed.com
